{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T23:47:35Z","timestamp":1782085655253,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02741-1","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T23:03:10Z","timestamp":1782082990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study"],"prefix":"10.1038","volume":"11","author":[{"given":"Zhe","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangdong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9914-5338","authenticated-orcid":false,"given":"Wenhao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueze","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengmian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinmo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huadan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2741_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA. Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA. Cancer J. Clin."},{"key":"2741_CR2","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","volume":"405","author":"TF Stoop","year":"2025","unstructured":"Stoop, T. F. et al. Pancreatic cancer. Lancet 405, 1182\u20131202 (2025).","journal-title":"Lancet"},{"key":"2741_CR3","doi-asserted-by":"publisher","first-page":"102269","DOI":"10.1016\/j.suronc.2025.102269","volume":"63","author":"A Hayasaki","year":"2025","unstructured":"Hayasaki, A. et al. Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy. Surg. Oncol. 63, 102269 (2025).","journal-title":"Surg. Oncol."},{"key":"2741_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41575-023-00856-2","volume":"21","author":"TF Stoop","year":"2024","unstructured":"Stoop, T. F. et al. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 21, 101\u2013124 (2024).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2741_CR5","doi-asserted-by":"publisher","first-page":"e073995","DOI":"10.1136\/bmj-2022-073995","volume":"383","author":"M Del Chiaro","year":"2023","unstructured":"Del Chiaro, M., Sugawara, T., Karam, S. D. & Messersmith, W. A. Advances in the management of pancreatic cancer. BMJ 383, e073995 (2023).","journal-title":"BMJ"},{"key":"2741_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker, M. et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 17, 801\u2013810 (2016).","journal-title":"Lancet Oncol"},{"key":"2741_CR7","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2741_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S2468-1253(19)30327-9","volume":"5","author":"PA Philip","year":"2020","unstructured":"Philip, P. A. et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol. Hepatol. 5, 285\u2013294 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2741_CR9","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","volume":"31","author":"H Ueno","year":"2013","unstructured":"Ueno, H. et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J. Clin. Oncol. 31, 1640\u20131648 (2013).","journal-title":"J. Clin. Oncol."},{"key":"2741_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/MPA.0000000000000501","volume":"45","author":"J-A Li","year":"2016","unstructured":"Li, J.-A. et al. Nab-Paclitaxel Plus S-1 shows increased antitumor activity in patient-derived pancreatic cancer xenograft mouse models. Pancreas 45, 425\u2013433 (2016).","journal-title":"Pancreas"},{"key":"2741_CR11","doi-asserted-by":"publisher","first-page":"e1406","DOI":"10.1093\/oncolo\/oyae171","volume":"29","author":"M Jin","year":"2024","unstructured":"Jin, M. et al. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study. The Oncologist 29, e1406\u2013e1418 (2024).","journal-title":"The Oncologist"},{"key":"2741_CR12","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg, Z. A. et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 402, 1272\u20131281 (2023).","journal-title":"Lancet"},{"key":"2741_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2468-1253(20)30330-7","volume":"6","author":"V Kunzmann","year":"2021","unstructured":"Kunzmann, V. et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol. Hepatol. 6, 128\u2013138 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2741_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejca.2022.12.014","volume":"181","author":"M Ozaka","year":"2023","unstructured":"Ozaka, M. et al. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Eur. J. Cancer 181, 135\u2013144 (2023).","journal-title":"Eur. J. Cancer"},{"key":"2741_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1470-2045(13)70021-4","volume":"14","author":"S Mukherjee","year":"2013","unstructured":"Mukherjee, S. et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 14, 317\u2013326 (2013).","journal-title":"Lancet Oncol"},{"key":"2741_CR16","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","volume":"315","author":"P Hammel","year":"2016","unstructured":"Hammel, P. et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA 315, 1844\u20131853 (2016).","journal-title":"JAMA"},{"key":"2741_CR17","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1200\/JCO-24-02210","volume":"43","author":"M Ducreux","year":"2025","unstructured":"Ducreux, M. et al. PRODIGE 29-UCGI 26 (NEOPAN): A Phase III randomized trial comparing chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma. J. Clin. Oncol. 43, 2255\u20132264 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2741_CR18","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.pan.2016.04.007","volume":"16","author":"H Imaoka","year":"2016","unstructured":"Imaoka, H. et al. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study. Pancreatology 16, 658\u2013664 (2016).","journal-title":"Pancreatology"},{"key":"2741_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5009\/gnl18419","volume":"14","author":"JE Lee","year":"2020","unstructured":"Lee, J. E. et al. Analysis of clinical predictive factors affecting the outcome of second-line chemotherapy for gemcitabine-refractory advanced pancreatic cancer. Gut Liver 14, 135\u2013143 (2020).","journal-title":"Gut Liver"},{"key":"2741_CR20","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1200\/JCO-24-01502","volume":"43","author":"R Fietkau","year":"2025","unstructured":"Fietkau, R. et al. Benefit of chemoradiotherapy versus chemotherapy after induction therapy for conversion of unresectable into resectable pancreatic cancer: the randomized CONKO-007 Trial. J. Clin. Oncol. 43, 3266\u20133278 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2741_CR21","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00280-018-3650-4","volume":"82","author":"W Zhang","year":"2018","unstructured":"Zhang, W. et al. Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial. Cancer Chemother. Pharmacol. 82, 655\u2013660 (2018).","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02741-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02741-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02741-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T23:03:11Z","timestamp":1782082991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02741-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2741"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02741-1","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in compliance with the ethical principles of the Declaration of Helsinki, and was approved by the Institutional Review Board (IRB) at each participating center, including: Institutional Review Board of Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (Approval No. HS-1751). Institutional Review Board of Xuanwu Hospital, Capital Medical University (Approval No. [2019]035). Institutional Review Board of Peking University First Hospital (Approval No. [2019]171). Institutional Review Board of the Fourth Hospital of Hebei Medical University (Approval No. 2020014).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}],"article-number":"243"}}